Biotech RadarJobs updated

COMPANY

Solid Biosciences Inc.

HQ: Charlestown, MA source · solidbio.com ↗ · New England

Clinical Phase 3

Location: Charlestown, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Duchenne Muscular Dystrophy Friedreich's Ataxia Catecholaminergic Polymorphic Ventricular Tachycardia SGT-003 SGT-212 SGT-501 SGT-001

$440.0MRaised (2 yrs)6Trials (company is sponsor)

Timeline

  1. Raise Private placement: $240M (total, as published), announced Mar 6, 2026. Source: company release on GlobeNewswire. source ↗
  2. Trial start Phase 1: A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) source ↗
  3. Trial start Phase 1: A Study of SGT-212 Gene Therapy in Friedreich's Ataxia source ↗
  4. Trial start Phase 3: A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE) source ↗
  5. Raise Follow-on offering: $200M (total, as published), announced Feb 18, 2025. Source: SEC filing. source ↗
  6. Trial start Phase 1/Phase 2: A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE) source ↗
  7. Trial start —: Evaluation of Home Based Assessments on Participants With DMD source ↗
  8. Trial start Phase 1/Phase 2: Microdystrophin Gene Transfer Study in Adolescents and Children With DMD source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $440.0M. Last 2 years.

Clinical trials (lead sponsor) 6

RecordTitlePhaseStatusStartPrimary completion
NCT07180355A Study of SGT-212 Gene Therapy in Friedreich's AtaxiaPhase 1RecruitingOct 22, 2025Mar 21, 2028 (estimated)
NCT07160634A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)Phase 3RecruitingOct 22, 20252029-01 (estimated)
NCT07148089A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)Phase 1RecruitingFeb 23, 20262027-06 (estimated)
NCT03368742Microdystrophin Gene Transfer Study in Adolescents and Children With DMDPhase 1/Phase 2Active, not recruitingDec 6, 2017Oct 15, 2026 (estimated)
NCT06138639A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)Phase 1/Phase 2RecruitingMay 6, 2024May 6, 2027 (estimated)
NCT05657938Evaluation of Home Based Assessments on Participants With DMDNot listedCompletedOct 13, 2022Apr 4, 2023 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback